{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:33:21Z","timestamp":1791340401505,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015763","name":"University of Szeged","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12253-020-00867-3","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T09:03:41Z","timestamp":1595235821000},"page":"2747-2754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-2989","authenticated-orcid":false,"given":"Anita","family":"Sejben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"K\u00f3sz\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kah\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Cserni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Zombori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"867_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1634\/theoncologist.8-6-521","volume":"8","author":"SH Giordano","year":"2003","unstructured":"Giordano SH (2003) Update on locally advanced breast cancer. Oncologist 8:521\u2013530. \nhttps:\/\/doi.org\/10.1634\/theoncologist.8-6-521","journal-title":"Oncologist"},{"key":"867_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/0973-1482.16086","volume":"1","author":"A Rustogi","year":"2005","unstructured":"Rustogi A, Budrukkar A, Dinshaw K, Jalali R (2005) Management of locally advanced breast cancer: evolution and current practice. J Can Res Ther 1:21\u201330. \nhttps:\/\/doi.org\/10.4103\/0973-1482.16086","journal-title":"J Can Res Ther"},{"key":"867_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/annonc\/mds324","volume":"23","author":"AM Thompson","year":"2012","unstructured":"Thompson AM, Moulder-Thompson SL (2012) Neoadjuvant treatment of breast cancer. Ann Oncol 23:231\u2013236. \nhttps:\/\/doi.org\/10.1093\/annonc\/mds324","journal-title":"Ann Oncol"},{"key":"867_CR4","doi-asserted-by":"publisher","first-page":"SP3","DOI":"10.1186\/bcr1709","volume":"9","author":"M Dani","year":"2007","unstructured":"Dani M, McDonnell J, Karp S, Jaffe V (2007) Do breast cancer tumours downsize as well as downgrade with neoadjuvant chemotherapy? Breast Cancer Res 9:SP3. \nhttps:\/\/doi.org\/10.1186\/bcr1709","journal-title":"Breast Cancer Res"},{"key":"867_CR5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.5858\/arpa.2012-0290-OA","volume":"137","author":"AD Corben","year":"2013","unstructured":"Corben AD, Abi-Raad R, Popa I, Chy T, Macklin EA, Koerner FC, Taghian AG, Brachtel EF (2013) Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy. A comparison between classifications and their practical application. Arch Pathol Lab Med 137:1074\u20131082. \nhttps:\/\/doi.org\/10.5858\/arpa.2012-0290-OA","journal-title":"Arch Pathol Lab Med"},{"key":"867_CR6","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","volume":"19","author":"M Kaufmann","year":"2012","unstructured":"Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508\u20131516. \nhttps:\/\/doi.org\/10.1245\/s10434-011-2108-2","journal-title":"Ann Surg Oncol"},{"key":"867_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.21873\/invivo.11594","volume":"33","author":"A Philipovskiy","year":"2019","unstructured":"Philipovskiy A, Corral J, Dwivedi KA, Heydarian R, Gaur S (2019) Efficacy of neoadjuvant versus adjuvant chemotherapy in Hispanic\/Latino (H\/L) women with local or locally advanced triple-negative breast cancer (TNBC). In Vivo 33:1227\u20131234. \nhttps:\/\/doi.org\/10.21873\/invivo.11594","journal-title":"In Vivo"},{"key":"867_CR8","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ, Panel Members (2015) Tailoring therapies \u2013 improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 26:1533\u20131546. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdv221","journal-title":"Ann Oncol"},{"key":"867_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Guidelines Committee ESMO (2015) Primary breast cancer: ESMO clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:8\u201330. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdv298","journal-title":"Ann Oncol"},{"key":"867_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","volume":"28","author":"E Provenzano","year":"2015","unstructured":"Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Residual disease characterization working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185\u20131201. \nhttps:\/\/doi.org\/10.1038\/modpathol.2015.74","journal-title":"Mod Pathol"},{"key":"867_CR11","first-page":"209","volume":"60","author":"G Cserni","year":"2016","unstructured":"Cserni G, Kulka J, Francz M, J\u00e1ray B, K\u00e1lm\u00e1n E, Kov\u00e1cs I, Kren\u00e1cs T, Udvarhelyi N, Vass L (2016) Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian consensus conference on breast Cancer. Magy Onkol 60:209\u2013228","journal-title":"Magy Onkol"},{"key":"867_CR12","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796\u20131804. \nhttps:\/\/doi.org\/10.1200\/JCO.2011.38.8595","journal-title":"J Clin Oncol"},{"key":"867_CR13","unstructured":"U.S. Food and Drug Administration (2014) Guidance for Industry: Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. \nhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM305501.pdf\n\n Accessed 19 Jan 2020"},{"key":"867_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer staging manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierly JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Madera M, Asare EA (2017) AJCC Cancer staging manual, 8th edn. Springer, Chicago","edition":"8"},{"key":"867_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/2229-516X.106353","volume":"2","author":"D Sethi","year":"2012","unstructured":"Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J (2012) Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res 2:111\u2013116. \nhttps:\/\/doi.org\/10.4103\/2229-516X.106353","journal-title":"Int J Appl Basic Med Res"},{"key":"867_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4132\/jptm.2016.02.02","volume":"50","author":"CK Park","year":"2016","unstructured":"Park CK, Jung WH, Koo JS (2016) Pathologic evaluation of breast cancer after neoadjuvant therapy. J Pathol Transl Med 50:173\u2013180. \nhttps:\/\/doi.org\/10.4132\/jptm.2016.02.02","journal-title":"J Pathol Transl Med"},{"key":"867_CR17","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE Jr, Taghian A, Wickerham DL, Wolmark N (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and bowel project B-18 and B-27. J Clin Oncol 30:3960\u20133966. \nhttps:\/\/doi.org\/10.1200\/JCO.2011.40.8369","journal-title":"J Clin Oncol"},{"key":"867_CR18","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","volume":"13","author":"B Chevallier","year":"1995","unstructured":"Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C et al (1995) Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564\u20131571. \nhttps:\/\/doi.org\/10.1200\/JCO.1995.13.7.1564","journal-title":"J Clin Oncol"},{"key":"867_CR19","first-page":"297","volume":"180","author":"DM Sataloff","year":"1995","unstructured":"Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180:297\u2013306","journal-title":"J Am Coll Surg"},{"key":"867_CR20","doi-asserted-by":"publisher","unstructured":"Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320\u2013327. \nhttps:\/\/doi.org\/10.1016\/s0960-9776(03)00106-1","DOI":"10.1016\/s0960-9776(03)00106-1"},{"key":"867_CR21","first-page":"114","volume":"90","author":"C Denkert","year":"2006","unstructured":"Denkert C, Schickling O, von Minckwitz G (2006) Preoperative chemotherapy in breast cancer and the development of new predictive markers. Verh Dtsch Ges Pathol 90:114\u2013123","journal-title":"Verh Dtsch Ges Pathol"},{"key":"867_CR22","doi-asserted-by":"crossref","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 28:4414\u20134422. 10.1200\/JCO.2007.10.6823","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"867_CR23","unstructured":"Wells CA, Amendoeira I, Bellocq JP, Bianchi S, Boecker W, Borisch B, Rasmussen B, Callagy GM, Chmielik E, Cordoba A, Cserni G, Decker T, DeGaetano J, Drijkoningen M, Ellis IO, Faverly DR, Foschini MP, Frkovi\u0107-Grazio S, Grabau D, Heikkil\u00e4 P, Iacovou E, Jacquemier J, Kaya H, Kulka J, Lacerda M, Liepniece-Karele I, Martinez-Penuela J, Quinn CM, Rank F, Regitnig P, Reiner A, Sapino A, Tot T, Van Diest P, Varga Z, Wesseling J, Zolota V, Zozaya-Alvarez E (2013) S2: pathology update. Quality assurance guidelines for pathology. In: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition, Supplements. Perry N, Broeders M, de Wolf C, T\u00f6rnberg S, Holland R, von Karsa L (eds.). European Commission, Office for Official Publications of the European Union, Luxembourg, pp. 73\u2013120"},{"key":"867_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/PPO.0b013e31816bdea2","volume":"14","author":"P Chollet","year":"2008","unstructured":"Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F (2008) A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J 14:128\u2013132. \nhttps:\/\/doi.org\/10.1097\/PPO.0b013e31816bdea2","journal-title":"Cancer J"},{"key":"867_CR25","doi-asserted-by":"publisher","unstructured":"Fowler AM, Mankoff DA, Joe BN (2017) Imaging neoadjuvant therapy response in breast cancer. Radiology 285:358-375. \nhttps:\/\/doi.org\/10.1148\/radiol.2017170180\n\n, 285, 358, 375","DOI":"10.1148\/radiol.2017170180"},{"key":"867_CR26","unstructured":"Royal College of Pathologists of Australasia (2012) Invasive breast cancer structured reporting protocol. \nhttps:\/\/www.rcpa.edu.au\/getattachment\/7b70b3e5-5dca-403f-893e-638815f487b1\/Protocol-invasive-breast-cancer.aspx\n\n. Accessed 22 Nov 2019"},{"key":"867_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2559.2006.02419.x","volume":"5","author":"K Lambein","year":"2011","unstructured":"Lambein K, Van de Vijver K, Faverly D, Colpaert C (2011) Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy. Belg J Clin Oncol 5:144\u2013153. \nhttps:\/\/doi.org\/10.1111\/j.1365-2559.2006.02419.x","journal-title":"Belg J Clin Oncol"},{"key":"867_CR28","unstructured":"Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Studiengruppe (2018) Diagnosis and treatment of patients with primary and metastatic breast cancer. \nhttps:\/\/www.ago-online.de\/fileadmin\/downloads\/leitlinien\/mamma\/2018-03\/EN\/Gesamt_PDF_Englisch\/Updated_Guidelines_2018.pdf\n\n."},{"key":"867_CR29","unstructured":"NHS Cancer Screening Programmes jointly with The Royal College of Pathologists (2005) Pathology reporting of breast disease. \nhttps:\/\/www.cmcanceralliance.nhs.uk\/application\/files\/3615\/4815\/5660\/Guidelines_for_NHSBSP58_January_2005_Reviewed_CNG_June_2010.pdf\n\n Accessed 18 Jan 2020"},{"key":"867_CR30","unstructured":"Integraal Kankercentrum Nederland (2012) Beoordeling na neoadjuvante chemo- of endocriene therapie. \nhttp:\/\/www.oncoline.nl\/breastcancer\n\n Accessed 26 June 2018"},{"key":"867_CR31","unstructured":"Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Hill KA, Kleer C, O\u2019Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, Simpson JF (2012) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. \nhttp:\/\/www.cap.org\/ShowProperty?nodePath=\/UCMCon\/Contribution%20Folders\/WebContent\/pdf\/cp-breast-invasive-16protocol-3300.pdf\n\n Accessed 22 Nov 2019"},{"key":"867_CR32","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35:1049\u20131060. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.63.1010","journal-title":"J Clin Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-020-00867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-020-00867-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-020-00867-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T10:27:29Z","timestamp":1599128849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-020-00867-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s12253-020-00867-3","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the institutional ethical committee of the Albert Szent-Gy\u00f6rgyi Clinical Centre of the University of Szeged.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}